27375283|t|Long-term lamivudine therapy in chronic hepatitis B
27375283|a|One to 5 years of therapy of chronic hepatitis B with oral nucleoside analogues result in significant clinical improvements, but effects of more prolonged therapy are not well defined. To describe outcomes of chronic hepatitis B with long-term lamivudine therapy. Forty-two patients with chronic hepatitis B treated with lamivudine were followed for 3.2-19.5 (median = 16.1) years. Therapy was switched to other agents (n = 16) if patients developed lamivudine resistance and relapse of disease. Among 22 HBeAg-positive patients, 17 (77%) became HBeAg negative, of whom 5 (23%) subsequently cleared HBsAg. Among 20 HBeAg-negative patients, 10 (50%) cleared HBsAg. The time to HBsAg clearance ranged from 0.9 to 16.8 (median = 9.3) years. Lamivudine resistance arose in 24 patients (57%) of whom 6 (25%) lost HBsAg. HBsAg clearance was not always accompanied by seroconversion; anti-HBs appearing concurrently in only five patients (33%). Nevertheless, HBsAg loss allowed for stopping therapy in all patients, none re-developing HBsAg or suffering relapse; all having normal alanine aminotransferase levels and no (n = 13) or unquantifiable HBV DNA levels (n = 2) when last seen. In contrast, seven of 27 patients (26%) who remained HBsAg-positive died of liver disease or liver cancer or underwent liver transplantation, all of whom had cirrhosis. Long-term viral suppression with nucleoside analogues leads to HBsAg loss in a substantial proportion of patients, particularly if HBeAg-negative. Serious outcomes during the first 10-20 years of treatment occur largely among patients with pre-existing cirrhosis who do not clear HBsAg with therapy.
27375283	0	28	Long-term lamivudine therapy	T061	C0420257
27375283	32	51	chronic hepatitis B	T047	C0524909
27375283	70	77	therapy	T061	C0087111
27375283	81	100	chronic hepatitis B	T047	C0524909
27375283	106	110	oral	T169	C1527415
27375283	111	131	nucleoside analogues	T114,T121	C1579410
27375283	154	162	clinical	T080	C0205210
27375283	163	175	improvements	T077	C2986411
27375283	181	191	effects of	T080	C1704420
27375283	197	214	prolonged therapy	T061	C0420257
27375283	249	257	outcomes	T058	C0033325
27375283	261	280	chronic hepatitis B	T047	C0524909
27375283	286	314	long-term lamivudine therapy	T061	C0420257
27375283	326	334	patients	T101	C0030705
27375283	340	359	chronic hepatitis B	T047	C0524909
27375283	360	372	treated with	T061	C0332293
27375283	373	383	lamivudine	T114,T121	C0209738
27375283	434	441	Therapy	T061	C0087111
27375283	464	470	agents	T121	C1254351
27375283	483	491	patients	T101	C0030705
27375283	502	512	lamivudine	T114,T121	C0209738
27375283	513	523	resistance	T038	C0013203
27375283	528	546	relapse of disease	T047	C0277556
27375283	557	571	HBeAg-positive	T034	C0392390
27375283	572	580	patients	T101	C0030705
27375283	598	612	HBeAg negative	T034	C0948827
27375283	643	650	cleared	T039	C0312550
27375283	651	656	HBsAg	T121,T129	C0019168
27375283	667	681	HBeAg-negative	T034	C0948827
27375283	682	690	patients	T101	C0030705
27375283	701	708	cleared	T039	C0312550
27375283	709	714	HBsAg	T121,T129	C0019168
27375283	728	733	HBsAg	T121,T129	C0019168
27375283	734	743	clearance	T039	C0312550
27375283	790	800	Lamivudine	T114,T121	C0209738
27375283	801	811	resistance	T038	C0013203
27375283	824	832	patients	T101	C0030705
27375283	860	865	HBsAg	T121,T129	C0019168
27375283	867	872	HBsAg	T121,T129	C0019168
27375283	873	882	clearance	T039	C0312550
27375283	913	927	seroconversion	T070	C4042908
27375283	929	937	anti-HBs	T059	C0948254
27375283	974	982	patients	T101	C0030705
27375283	1004	1009	HBsAg	T121,T129	C0019168
27375283	1036	1043	therapy	T061	C0087111
27375283	1051	1059	patients	T101	C0030705
27375283	1080	1085	HBsAg	T121,T129	C0019168
27375283	1099	1106	relapse	T047	C0277556
27375283	1126	1157	alanine aminotransferase levels	T059	C0201836
27375283	1192	1206	HBV DNA levels	T059	C3641250
27375283	1256	1264	patients	T101	C0030705
27375283	1284	1298	HBsAg-positive	T034	C0149709
27375283	1299	1303	died	T033	C1306577
27375283	1307	1320	liver disease	T047	C0023895
27375283	1324	1336	liver cancer	T191	C0345904
27375283	1350	1371	liver transplantation	T061	C0023911
27375283	1389	1398	cirrhosis	T047	C0023890
27375283	1400	1409	Long-term	T079	C0443252
27375283	1410	1415	viral	T005	C0042776
27375283	1416	1427	suppression	T061	C0021079
27375283	1433	1453	nucleoside analogues	T114,T121	C1579410
27375283	1463	1468	HBsAg	T121,T129	C0019168
27375283	1491	1501	proportion	T081	C1709707
27375283	1505	1513	patients	T101	C0030705
27375283	1531	1545	HBeAg-negative	T034	C0948827
27375283	1555	1563	outcomes	T058	C0033325
27375283	1596	1605	treatment	T061	C0087111
27375283	1626	1634	patients	T101	C0030705
27375283	1640	1652	pre-existing	T080	C2347662
27375283	1653	1662	cirrhosis	T047	C0023890
27375283	1674	1679	clear	T039	C0312550
27375283	1680	1685	HBsAg	T121,T129	C0019168
27375283	1691	1698	therapy	T061	C0087111